Market Newsdesk

Atlanta, GA, Sept. 14, 2026 (GLOBE NEWSWIRE) — Piedmont Realty Trust, Inc. (NYSE: PDM) (“Piedmont”) today announced that its operating partnership, Piedmont Operating Partnership, LP (the “Operating Partnership”), priced its offering of $200,000,000 aggregate principal amount of 2.875% exchangeable senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Piedmont will fully and unconditionally guarantee the notes on a senior, unsecured basis. The issuance and sale of the notes are scheduled to settle on September 17, 2026, subject to customary closing conditions. The Operating Partnership also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $30,000,000 aggregate principal amount of notes.

The notes will be senior, unsecured obligations of the Operating Partnership and will accrue interest at a rate of 2.875% per annum, payable semi-annually in arrears on February 1 and August 1 of each year, beginning on February 1, 2027. The notes will mature on February 1, 2031, unless earlier exchanged or redeemed or repurchased. Before November 1, 2030, noteholders will have the right to exchange their notes only upon the occurrence of certain events. From and after November 1, 2030, noteholders may exchange their notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. The Operating Partnership will settle exchanges by paying or delivering, as applicable, cash or a combination of cash and shares of Piedmont’s common stock, at the Operating Partnership’s election. The initial exchange rate is 79.0514 shares of Piedmont’s common stock per $1,000 principal amount of notes, which represents an initial exchange price of $12.65 per share of Piedmont’s common stock. The initial exchange price represents a premium of approximately 37.5% over the last reported sale price of $9.20 per share of Piedmont’s common stock on September 14, 2026. The exchange rate and exchange price will be subject to adjustment upon the occurrence of certain events.

The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at the Operating Partnership’s option at any time, and from time to time, on or after August 6, 2029 and on or before the 60th scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of Piedmont’s common stock exceeds 130% of the exchange price for a specified period of time and certain other conditions are satisfied. In addition, the notes will be redeemable, in whole or in part (subject to certain limitations), at the Operating Partnership’s option at any time to the extent necessary to preserve Piedmont’s status as a real estate investment trust for U.S. federal income tax purposes, so long as certain conditions are satisfied. The Operating Partnership may also redeem the notes, in whole but not in part, at any time on or before the 60th scheduled trading day immediately before the maturity date, if certain conditions are satisfied and if the aggregate principal amount of notes that remains outstanding at such time is less than 10% of the aggregate principal amount of notes initially issued in connection with the offering. In each case, the redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

If a “fundamental change” (as defined in the indenture that will govern the notes) occurs, then, subject to a limited exception, noteholders may require the Operating Partnership to repurchase their notes for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date.

The notes will be entitled to the benefits of a registration rights agreement pursuant to which Piedmont will agree to register, under the Securities Act, the resale of the shares of Piedmont’s common stock, if any, issuable upon exchange of the notes within specified time periods and subject to certain limitations.

The Operating Partnership estimates that the net proceeds from the offering will be approximately $194.3 million (or approximately $223.5 million if the initial purchasers fully exercise their option to purchase additional notes), after deducting the initial purchasers’ discounts and commissions and the Operating Partnership’s estimated offering expenses. The Operating Partnership intends to use a portion of the net proceeds from this offering, together with the net proceeds from the settlement of certain forward sale transactions entered into under Piedmont’s at-the-market equity program, cash on hand and borrowings under its line of credit, to redeem all of its outstanding 9.250% senior notes due 2028 (the “2028 notes”) and pay the applicable make-whole premium and accrued and unpaid interest with respect thereto. If the initial purchasers exercise their option to purchase additional notes, the Operating Partnership will use the additional proceeds to redeem its outstanding 2028 notes and proportionally decrease the borrowings under its line of credit used to redeem the outstanding 2028 notes.

The Operating Partnership expects to use approximately $50 million of the net proceeds from the offering to repurchase 5,434,782 shares of Piedmont’s common stock from certain purchasers of the notes in privately negotiated transactions effected through one of the initial purchasers or its affiliate concurrently with the pricing of the notes (the “concurrent share repurchase”). The price per share of Piedmont’s common stock repurchased in the concurrent share repurchase is equal to $9.20, which was the last reported sale price per share of Piedmont’s common stock on the New York Stock Exchange on September 14, 2026. This concurrent share repurchase could increase (or reduce the size of any decrease in) the market price of Piedmont’s common stock prior to, concurrently with or shortly after the pricing of the notes, and could have resulted in a higher effective exchange price for the notes. The Operating Partnership cannot predict the magnitude of such market activity or the overall effect it will have on the market price of the notes and/or the market price of Piedmont’s common stock.

The offer and sale of the notes, the guarantee and any shares of Piedmont’s common stock issuable upon exchange of the notes have not been registered under the Securities Act or any other securities laws, and the notes, the guarantee and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. Although the Operating Partnership and Piedmont will enter into a registration rights agreement pursuant to which Piedmont will agree to register, under the Securities Act, the resale of the shares of Piedmont’s common stock, if any, issuable upon exchange of the notes, the registration rights agreement will contain significant limitations, and a resale registration statement may not be available at the time investors wish to resell the shares of Piedmont’s common stock, if any, issuable upon exchange of their notes. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any shares of Piedmont’s common stock issuable upon exchange of the notes, nor will there be any sale of the notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.

About Piedmont Realty Trust

Piedmont Realty Trust™ (NYSE: PDM) is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of approximately 16 MM SF of Class A properties across major U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into premier “Piedmont PLACEs” that enhance each client’s workplace experience.

Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Piedmont intends for all such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act, as applicable. Such information is subject to certain known and unknown risks and uncertainties, which could cause actual results to differ materially from those anticipated. Therefore, such statements are not intended to be a guarantee of Piedmont`s performance in future periods. Such forward-looking statements can generally be identified by Piedmont’s use of forward-looking terminology such as “may,” “will,” “expect,” “intend,” “anticipate,” “estimate,” “believe,” “continue” or similar words or phrases that indicate predictions of future events or trends or that do not relate solely to historical matters, and include statements regarding the completion of the offering and the concurrent share repurchase; and the intended use of the net proceeds from the offering. These statements are based on beliefs and assumptions of Piedmont’s management, which in turn are based on information available at the time the statements are made.

The following are some of the factors that could cause Piedmont’s actual results and its expectations to differ materially from those described in Piedmont’s forward-looking statements: economic, regulatory, socio-economic, technological (e.g., artificial intelligence and machine learning, virtual meeting platforms, etc.), and other changes that impact the real estate market generally, the office sector or the patterns of use of commercial office space in general, or the markets where we primarily operate or have high concentrations of revenue; the impact of competition on our efforts to renew existing leases or re-let space on terms similar to existing leases; lease terminations, lease defaults, lease contractions, or changes in the financial condition of our tenants, particularly by one of our large tenants; impairment charges on our long-lived assets or goodwill resulting therefrom; the success of our real estate strategies and investment objectives, including our ability to implement successful redevelopment and development strategies or identify and consummate suitable acquisitions and divestitures; the illiquidity of real estate investments, including economic changes, such as fluctuating interest rates, costs of construction, improvements and redevelopments, and available financing, which could impact the number of buyers/sellers of our target properties, and regulatory restrictions to which real estate investment trusts (“REITs”) are subject and the resulting impediment on our ability to quickly respond to adverse changes in the performance of our properties; the risks and uncertainties associated with our acquisition and disposition of properties, many of which risks and uncertainties may not be known at the time of acquisition or disposition; development and construction delays, including the potential of supply chain disruptions, and resultant increased costs and risks; future acts of terrorism, civil unrest, or armed hostilities in any of the major metropolitan areas in which we own properties; risks related to the occurrence of cybersecurity incidents, including cybersecurity incidents against us or any of our properties, vendors, or tenants, or a deficiency in our identification, assessment or management of cybersecurity threats impacting our operations and the public’s reaction to reported cybersecurity incidents, including the reputational impact on our business and value of our common stock; costs of complying with governmental laws, regulations and policies, including environmental standards imposed on office building owners; uninsured losses or losses in excess of our insurance coverage, and our inability to obtain adequate insurance coverage at a reasonable cost; additional risks and costs associated with directly managing properties occupied by government tenants, such as potential changes in the political environment, a reduction in federal or state funding of our governmental tenants, government layoffs or an increased risk of default by government tenants during periods in which state or federal governments are shut down or on furlough; significant price and volume fluctuations in the public markets, including on the exchange on which we listed our common stock; risks associated with incurring mortgage and other indebtedness, including changing capital reserve requirements on our lenders and rising interest rates for new debt financings; a downgrade in our credit ratings, the credit ratings of the Operating Partnership or the credit ratings of our or the Operating Partnership’s unsecured debt securities, which could, among other effects, trigger an increase in the stated rate of one or more of our unsecured debt instruments; the effect of future offerings of debt or equity securities on the value of our common stock; additional risks and costs associated with adverse U.S. global and economic conditions, inflation and potential increases in the rate of inflation, including the impact of a possible recession, uncertainty and volatility in financial markets, and any changes in governmental rules, regulations, and fiscal policies; uncertainties associated with environmental and regulatory matters; changes in the financial condition of our tenants directly or indirectly resulting from geopolitical developments that could negatively affect important supply chains and international trade, the termination or threatened termination of existing international trade agreements, or the implementation of tariffs or retaliatory tariffs on imported or exported goods; the effect of any litigation to which we are, or may become, subject; additional risks and costs associated with owning properties occupied by tenants in particular industries, such as oil and gas, hospitality, travel, co-working, etc., including risks of default during start-up and during economic downturns; changes in tax laws impacting REITs and real estate in general, as well as our ability to continue to qualify as a REIT under the Internal Revenue Code of 1986, as amended, or other tax law changes which may adversely affect our stockholders; the future effectiveness of our internal controls and procedures; and other factors, including the risk factors discussed under Item 1A. of our Annual Report on Form 10-K for the year ended December 31, 2025.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Piedmont cannot guarantee the accuracy of any such forward-looking statements contained in this press release, and Piedmont does not intend to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Research Analysts/ Institutional Investors Contact:
770-418-8592
[email protected]

Phoenix, AZ, Sept. 14, 2026 (GLOBE NEWSWIRE) — InnSuites Hospitality Trust (NYSE American: IHT) announced today that it has received notice from the NYSE-American that the Compliance Plan previously submitted on July 24, 2026 has been accepted, and the Trust has been granted a plan period through December 24, 2027. Although the Trust is not currently in compliance with NYSE American continued listing standards, its listing is being continued pursuant to an extension.

The Trust timely submitted the compliance plan to NYSE American on July 24, 2026, advising NYSE American of actions the Trust has taken or intends to take to regain compliance with the continued listing standards. The 18-month cure period allows the Trust to regain compliance by/before December 24, 2027.

The Trust recently increased stockholders’ equity by approximately $3.0 million, as part of IHT’s efforts in regaining compliance. The Trust continues to pursue strategic alternatives, including a potential reverse merger or other strategic transactions, with operational initiatives underway intended to improve hotel gross operating profits.

All such actions are subject to applicable board or committee approval, accounting confirmation, NYSE American requirements, securities law compliance, market conditions, and other conditions. There can be no assurance that NYSE American will accept the Trust’s compliance plan, that any proposed transaction or initiative will be completed, that the Trust will regain compliance within the plan period, or that the Trust will otherwise continue to satisfy other NYSE American continued listing standards.

IHT has exceeded $4 million in total hotel revenues for the Fiscal First Half of the current Fiscal Year (February 1, 2026 through January 31, 2027), including combined hotel July revenue of $600,293, an all-time record for the month of July for the two hotels combined. Management believes these operating results, together with the Trust’s ongoing review of capitalization alternatives, strategic alternatives, and selected diversification opportunities, support the Trust’s efforts to develop, submit, and successfully complete a credible compliance plan to NYSE American.

RRF LLLP, the 76% owned subsidiary Management Company for IHT, manages the IHT Hotels, as well as InnDependent Boutique Collection (IBC Hotels, LLC). IBC and UniGen are both diversification opportunities for IHT. IHT has received a recent surge of interest in a merger, based on its valuable NYSE American trading platform. IHT is further attractive with its recent $3 million increased equity base.

Consolidated Net Income for the Fiscal First Quarter was $74,702, an increase of 48% from the prior year Fiscal First Quarter ended April 30, 2026 (February 1, 2026, through April 30, 2026).

Consolidated Net Income before non-cash expense items of depreciation and non-cash Best Western Travel Rewards credit expenses, was a positive profit of $307,326 for the 2027 Fiscal First Quarter.

The continued growing demand for electricity from data centers plus the influx of electric vehicles, as well as projected growing needs for artificial intelligence, increased demand for electricity over the next five years is projected to approximately double, and bodes well for the IHT investment in UniGen Power, Inc. This product is a potentially power industry disruptive economical, relatively clean energy, cost effective electric generation innovation. Even though it is high risk, UniGen offers IHT high upside potential.

On February 20, 2026, James Wirth, IHT President, was elected Chairman, CEO, and President of UniGen, while Marc Berg, IHT EVP, was elected as Vice Chairman, EVP, and Secretary/Treasurer of UniGen, with plans to rejuvenate the UniGen progress to benefit all the UniGen debt and equity holders, including IHT. Target date for the first two prototype engines to be ready for testing is in less than two years.

IHT management believes that due to real estate held on the books of IHT at book values significantly below current market value, due to clean energy diversification high profit potential ahead, IBC independent hotel services prospects, a potential merger or reverse merger future, plus improving hospitality profitability before non-cash depreciation and other non-cash items, along with the recent increase of IHT equity of $3 million, the IHT future looks bright.

Our most recent dividend paid in February 2026, at the start of the current Fiscal Year 2027, extended IHT’s uninterrupted, continuous annual dividends to 56 years, since 1971, when IHT was first listed on the NYSE. IHT future plans include annual dividends, with the next dividend tentatively scheduled for February 15, 2027, at the beginning of the 2028 Fiscal Year.

Management believes that the Trust’s hotel operating results, real estate assets, capitalization initiatives, and strategic alternatives provide a positive basis for the Trust. There can be no assurance that any of these initiatives will be successful, that the Trust will complete any equity-enhancing transaction, or that the Trust will regain or maintain compliance with NYSE American continued listing standards.

For more information, visit www.innsuitestrust.com and www.innsuites.com.

Forward-Looking Statements

With the exception of historical information, matters discussed in this news release may include “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements include, without limitation, statements regarding the Trust’s intended submission of a compliance plan to NYSE American; the Trust’s ability to regain compliance with NYSE American continued listing standards; potential actions to increase stockholders’ equity; potential conversion of related-party indebtedness into IHT equity; potential capital-raising, capitalization restructuring, or strategic transactions; potential merger or reverse merger opportunities; operating initiatives; hotel operating trends; future annual dividends; diversification opportunities; opportunities involving IBC Hotels, LLC and UniGen Power, Inc.; and expected costs, benefits, timing, or results of any of the foregoing.

Actual developments, business decisions, results, and future actions may differ materially from those expressed or implied by such forward-looking statements. Important factors, among others, that could cause actual results and future actions to differ materially include: NYSE American’s review of the Trust’s compliance plan; the Trust’s ability to complete any equity-enhancing transaction; the Trust’s ability to regain and maintain compliance with NYSE American continued listing standards; the availability, terms, and timing of financing or capitalization alternatives; the outcome of any related-party transaction review; accounting treatment of proposed transactions; required board, committee, NYSE American, shareholder, or other approvals; market conditions; hotel operating results; seasonality; liquidity needs; the outcome of any merger or reverse merger or strategic transaction discussions; the timing and success of potential diversification initiatives; risks relating to IBC Hotels, LLC and UniGen Power, Inc.; economic effects of international conflicts, tariffs, inflation, interest rates, travel industry conditions, and other macroeconomic factors; and the risks described in the Trust’s filings with the Securities and Exchange Commission.

The Trust undertakes no obligation to update any forward-looking statement contained in this news release to reflect events or circumstances after the date of this news release, except as required by applicable law.

FOR FURTHER INFORMATION:

Marc Berg, Executive Vice President
602-944-1500
email: [email protected]

INNSUITES HOSPITALITY CENTRE
1730 E. NORTHERN AVENUE, #122
Phoenix, Arizona 85020
Phone: 602-944-1500

NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP (“Wolf Haldenstein”), a nationally recognized securities litigation law firm, announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Papa
John’s International, Inc. (“Papa John’s” or the “Company”) (NASDAQ: PZZA) common stock between August 7, 2025 and August 5, 2026, inclusive (the “Class Period”).

Investors who purchased Papa John’s shares during the class period and suffered losses may be eligible to participate in the case, with the lead-plaintiff deadline set for November 2, 2026.

PLEASE CLICK HERE TO SUBMIT CONTACT AND TRADE INFORMATION

The filed complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failing to disclose material adverse facts to investors, including that:

• Defendants created the false impression that they
  possessed reliable information pertaining to the effectiveness and ongoing
  impact of the Company’s strategic transformation as well as their resulting
  projected growth outlook for the North American region;
• Defendants also minimized the risk of cautious consumer sentiment, competition, promotional seasonality, and more general macroeconomic fluctuation;
• In truth, Papa Johns’ strategic transformation was taking considerably longer than the projections had suggested and the Company was simply ill equipped to “meet the consumer where they’re at;” and
• As a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

On August 6, 2026, Papa Johns issued its second quarter 2026 financial results, reporting an 8.3% decline in North American comparable sales. The Company also reduced its fiscal 2026 outlook, expecting “global system-wide sales to decline between 2% and 4% compared to last year and adjusted EBITDA between $180 million to $190 million,” and suspended its quarterly dividend. During the related conference call, CEO Todd Allan Penegor stated that “it’s clear that our transformation is taking longer than expected” and “we must execute better and move faster.”

On this news, Papa Johns’ stock price fell $5.11 or 17.18%, to close at $24.64 per share on August 6, 2026,

WHY WOLF HALDENSTEIN?

This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven record of protecting the rights of investors.

We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.

There is no cost or obligation to speak with an attorney.

Contact:

• Phone: (800) 575-0735 or (212) 545-4774
• Email: 
  [email protected]
• Contact Person: Gregory Stone, Director of Case and Financial Analysis

Firm Website: 
Wolf Haldenstein Adler Freeman & Herz LLP

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) — This corrected press release is being issued to correct the merger exchange ratio that was incorrectly stated in the press release of Impact Biomedical Inc. (the “Company” or “Impact”) dated September 11, 2026. The original press release incorrectly stated that Impact stockholders would receive one (1) share of Zoar Limited for every four (4) shares of Impact Common Stock (defined below). The correct exchange ratio, as set forth in the Merger and Share Exchange Agreement as Exhibit 2.1 to the current report on Form 8-K dated June 23, 2025 (Accession No.0001641172-25-016002), is one (1) share of Zoar Limited for every one (1) share of Impact Common Stock held immediately prior to the effective time of the merger, after giving effect to the Reverse Stock Split. No other changes have been made to the original press release.

The Company today announced that the Company’s Board of Directors has approved a 1 for 12.62 reverse stock split of the Company’s issued and outstanding common stock, par value $0.001 per share (the “Common Stock”). The reverse stock split will become effective at 12:01 a.m., Eastern Time, on September 23, 2026. Starting with the opening of trading on that date, the Company’s Common Stock will continue to trade on the NYSE American Exchange under the ticker symbol “IBO” and will trade under a new CUSIP number to be assigned in connection with the reverse stock split.

On December 30, 2025, the Company’s stockholders approved a second reverse stock split of the Company’s Common Stock at a ratio of not less than 1-for-12.48 and not more than 1-for-50 to be implemented at the discretion of the Chief Executive Officer. The Reverse Stock Split is intended to support the Company’s efforts in connection with the proposed business combination transaction and its continued-listing objectives. The Reverse Stock Split does not assure that the Company will satisfy applicable NYSE American continued-listing standards, obtain approval of any applicable listing application, or complete the proposed transaction.

The merger of Impact Biomedical Inc. and Zoar, upon approval and closing, is expected to result in a pharmaceutical company focused on the development and supply of Active Pharmaceutical Ingredients and intermediates for special therapeutic treatment areas.

Read the original merger announcement here: https://www.sec.gov/Archives/edgar/data/1834105/000164117225016002/ex99-1.htm

Upon completion of the proposed merger, Impact stockholders are expected to receive one (1) share of Zoar Limited for every one (1) share of Impact Common Stock held immediately prior to the effective time of the merger, after giving effect to the Reverse Stock Split.

The reverse stock split will combine every 12.62 shares of the Company’s issued and outstanding Common Stock into one (1) new share of Common Stock. No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive a fractional share will have their fractional share rounded up to the next whole share. Other than adjustments resulting from the treatment of fractional shares, the Reverse Stock Split will affect all stockholders uniformly and will not alter any stockholder’s percentage ownership interest in the Company.

Stockholders holding shares in book-entry form or through a bank, broker, or other nominee do not need to take any action. Impact Biomedical’s transfer agent, Equiniti Trust Company, LLC (“Equiniti”), will manage the exchange. Stockholders of record who hold physical certificates will receive a letter of transmittal from Equiniti with instructions for exchanging their shares. Unless a stockholder specifically requests new paper certificates (or holds restricted shares), new shares will be issued electronically in book-entry form.

Following the reverse stock split, the total number of shares of Common Stock outstanding is expected to decrease from approximately 107,821,231 to 8,543,679 subject to minor adjustments due to rounding. Corresponding proportional adjustments will also be made to:

	●	Outstanding equity awards and related exercise prices
	●	Shares available under equity incentive plans
	●	Other relevant share-based agreements

The reverse stock split will not affect the total number of authorized shares, and all resulting shares will remain fully paid and non-assessable.

Additional information about the reverse stock split can be found in the Company’s definitive information statement filed with the Securities and Exchange Commission (the “SEC”) on December 30, 2025, which is available free of charge at the SEC’s website, www.sec.gov.

Additional Information and Where to Find It

In connection with the proposed transaction, Zoar Limited has filed with the SEC a registration statement on Form F-4 Registration Statement (the “Registration Statement”) that includes a preliminary proxy statement/prospectus (a “Proxy Statement/Prospectus”). After the Registration Statement is declared effective, a definitive Proxy Statement/Prospectus will be mailed to Impact’s stockholders as of a record date to be established by Impact’s board of directors for voting on the proposed merger. Impact may also file other relevant documents regarding the proposed merger with the SEC. Impact’s stockholders and other interested persons are advised to read, once available, the preliminary Proxy Statement/Prospectus and any amendments thereto and, once available, the definitive Proxy Statement/Prospectus, in connection with Impact’s solicitation of proxies for its special meeting of stockholders to be held to approve, among other things, the Business Combination, because these documents will contain important information about Impact, Zoar Labs, PubCo and the proposed merger. Stockholders of Impact may also obtain a copy of the preliminary or definitive Proxy Statement, once available, as well as other documents filed with the SEC regarding the proposed merger and other documents filed with the SEC, without charge, at the SEC’s website located at www.sec.gov or by directing a request to: Impact’s Chief Executive Officer at 1400 Broadfield Blvd., Suite 130, Houston, TX.

Participants in the Solicitation

Impact, PubCo, Zoar Labs, and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from Impact stockholders in connection with the proposed merger. Information about Impact’s directors and executive officers is set forth in Impact’s filings with the SEC. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the Registration Statement and the proxy statement/prospectus included therein.

About Zoar Limited:

Zoar Ltd. is a global pharmaceutical company focused on the development and manufacturing of active pharmaceutical ingredients, formulations, orphan drugs, and contract development and manufacturing services for pharmaceutical and biotechnology companies worldwide.

About IBO:

Impact Biomedical Inc. discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships.

Safe Harbor Disclosure:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date.

Investor Relations:

[email protected]

www.impactbiomedinc.com

NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP (“Wolf Haldenstein”), a nationally recognized securities litigation law firm, announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers
securities between August 4, 22025,and July 29, 2026 (the “Class Period”).

Investors who purchased Hims & Hers shares during the class period and suffered losses may be eligible to participate in the case, with the lead-plaintiff deadline set for November 2, 2026.

PLEASE CLICK HERE TO SUBMIT CONTACT AND TRADE INFORMATION

The filed complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failing to disclose material adverse facts to investors, including that

• the Company shared consumers’ health information with third-party advertising platforms;

• the Company charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is “right for them;”

• the foregoing conduct subjected the Company to regulatory scrutiny;

• because of the foregoing, the Company was reasonably likely to incur fees and penalties; and

• because of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On July 29, 2026, the Federal Trade Commission (“FTC”), the People of the State of California through Los Angeles County Counsel and the Utah Division of Consumer Protection sued Hims & Hers in the Northern District of California. According to the FTC, the action alleges that Hims & Hers fails to clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find treatment that is “right for them.” The FTC also alleges that the company has made it difficult for consumers to cancel subscriptions and misled consumers about
keeping their health information private. The FTC alleges that Hims shared consumers’ health information with Meta, Snap and other third parties.

Following this news, the price of Hims & Hers stock fell $4.32 per share, or 14.73%, to close at $25.00 per share on July 29, 2026.

WHY WOLF HALDENSTEIN?

This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven record of protecting the rights of investors.

We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.

There is no cost or obligation to speak with an attorney.

Contact:

• Phone: (800) 575-0735 or (212) 545-4774

• Email:
  [email protected]

• Contact Person: Gregory Stone, Director of Case and Financial Analysis

Firm Website: 
Wolf Haldenstein Adler Freeman & Herz LLP

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

— Yet ISS gives Anavex Board a free pass on years of failed governance and shareholder value destruction by supporting the current board’s nominees – 

— It’s too little, too late after a few months of the incumbent board’s half-measures, so stockholders are encouraged to vote

the GOLD Universal Proxy Card

to elect PVG’s six nominees to help Anavex realize the full potential of its valuable assets while there’s still time —

CENTENNIAL, Colo., Sept. 14, 2026 (GLOBE NEWSWIRE) — PVG Asset Management Corp. (“PVG”), a stockholder of 337,663 shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) (“Anavex” or the “Company”) is troubled that Institutional Shareholder Services (“ISS”) recently supported the current board’s nominees, in a report issued on September 11, 2026, even after the proxy advisory firm acknowledged years of failed governance and shareholder value destruction.

ISS, in its recent Anavex report⁽¹⁾:

• Stated that, “The board historically failed to exercise effective oversight of management, which led to challenges resulting from an unsuccessful European drug application.”
• Found that “it appears that the board played a passive role and failed to exercise effective oversight,” during the more-than 12-year tenure of the previous CEO that ended on April 30, 2026.
• Revealed the stunning news that, “In engagement with ISS, the board further reported that it had minimal meetings with corporate officers beyond the former CEO during his tenure.”
• Assigned its lowest-possible ISS “QualityScore” of 10 for “Audit & Risk Oversight” at Anavex, as of September 11, 2026.
• Noted that Anavex’s audit, compensation, and nominating and corporate governance “committees currently have the same person chairing each, a situation that has persisted since 2018. In engagement with ISS, the board stated that in the future, the committees will have different individuals chairing each. Even so, it is difficult to interpret the current arrangement as consistent with the best interests of shareholders, particularly when considered alongside recent developments.” ISS added that “it is unclear why the key committees remain chaired by one individual (particularly because the concentration of power in one individual contributed to recent challenges), and the vote standard in this election can potentially act as an entrenchment mechanism.”
• Recognized that “Failure to remediate material weakness in a timely manner could indicate a failure of the audit committee to provide sufficient oversight over the financial reporting process at the company.”
• Noted that only one current director owns stock, totaling just 5,000 shares, stating, “The company does not disclose sufficient stock ownership guidelines or holding period requirements for executives. Such provisions are good governance practices and mitigate compensation-related risk. Adoption of these policies would be beneficial for shareholders.”
• Illustrated how AVXL’s negative one-, three-, and five-year total shareholder returns have clearly underperformed peers and the Nasdaq Biotech Index, as of July 23 and September 4 of 2026.
• Found “puzzling elements of the board’s defense, including an allegation that the dissident is attempting to take control of the company ‘without paying [a] premium.’ While the dissident is indeed seeking board control, pointing out the lack of a control premium paid needlessly conflates board and ownership control.”

⁽¹⁾

Permission to use quotations from ISS was neither sought nor obtained.

“We believe time is off the essence to help Anavex realize the full potential of its valuable assets and arrest the staggering shareholder value destruction that has taken place on the current board’s watch,” said Patrick S. Adams, President of PVG Asset Management Corporation. “In addition to governance failures we have previously sounded the alarm on, ISS reveals the Board admits it did not regularly meet with any Anavex officer beyond the former CEO, for more than 12 years apparently, until he was fired about four months ago. The current board’s nominees include incumbents who have had up to nine years to right some of these wrongs, including the current chairperson who has had a full five years as an independent director to exercise effective oversight.

“Yet, ISS gives a free pass to these same directors and their hand-picked nominees for about four months of half-measures, including the appointment of an interim CEO with no executive experience. It’s too little, too late.”

PVG believes Anavex requires a new Board to provide appropriate oversight, as well as an experienced biotechnology CEO capable of restoring credibility with investors, securing the capital necessary to advance key clinical programs, and creating long-term value for all stockholders.

Investor Conference Call

As previously announced, PVG will host an investor conference call to discuss its campaign for change in the Anavex Board of Directors at the upcoming 2026 Annual Meeting of Stockholders.

Date: Wednesday, September 16, 2026

Time: 10:00 a.m. Eastern Time

Webcast/Conference Call:
https://edge.media-server.com/mmc/go/pvg2026townhall

Replay Information:
https://edge.media-server.com/mmc/go/pvg2026townhall

PVG encourages all stockholders to carefully review its proxy materials and vote the GOLD Universal Proxy Card to elect PVG’s six nominees at the 2026 Annual Meeting.

For additional information regarding PVG’s campaign for change at Anavex, please visit: www.AnavexVotePVG.com.

If you have any questions, require assistance in voting your GOLD universal proxy card, or need additional copies of PVG Group’s proxy materials, please contact: 1055 Washington Boulevard, Suite 520 Stamford, CT 06901 Stockholders may call toll-free: (877) 972-0090 Banks and brokers call collect: (203) 972-9300 E-mail: [email protected]

Participants in the Solicitation

The participants in PVG’s solicitation of proxies are PVG Asset Management Corporation, Patrick S. Adams, Jason Kolbert, Ralf von Ziegesar, Rene Mora, John Boris and Curtis Hogue (collectively, the “Participants”). Information concerning the identity of the Participants and a description of their direct or indirect interests, by security holdings or otherwise, is included in PVG’s Definitive Proxy Statement and related SEC filings.

Forward-Looking Statements

This release and any related communications contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are not historical facts, including statements regarding PVG’s plans, objectives, beliefs, strategies and expectations relating to the 2026 Annual Meeting, the proxy solicitation, the Company, the Company Board of Directors, the PVG nominees, stockholder value and the potential outcome of PVG’s solicitation.

These statements may be identified by words such as “believes,” “expects,” “anticipates,” “plans,” “intends,” “estimates,” “may,” “will,” “would,” “could,” “should” and similar expressions, or the negative thereof. Actual results may differ materially from those projected or contemplated by these forward-looking statements due to various risks and uncertainties, including those described in applicable filings made by the Company and PVG with the SEC.

Stockholders are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date made. PVG and the Participants do not undertake any obligation to update or revise any forward-looking statements, except as required by applicable law.

Important Additional Information and Where to Find It

PVG, together with the other Participants, has filed a definitive proxy statement on Schedule 14A and accompanying GOLD Universal Proxy Card with the SEC in connection with the solicitation of proxies from stockholders of the Company relating to the 2026 Annual Meeting.

STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ THE DEFINITIVE PROXY STATEMENT, THE ACCOMPANYING GOLD UNIVERSAL PROXY CARD, ANY AMENDMENTS OR SUPPLEMENTS THERETO, AND ANY OTHER DOCUMENTS FILED BY PVG WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BEFORE MAKING ANY VOTING DECISION BECAUSE THEY CONTAIN IMPORTANT INFORMATION.

The Definitive Proxy Statement, GOLD Universal Proxy Card and other relevant materials filed by PVG with the SEC are available at no charge at the SEC’s website at https://www.sec.gov/.

Contact:


Patrick S. Adams
PVG Asset Management Corporation
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/33d49f79-50c6-40bf-b759-4542d16fbac0